Alembic Pharmaceuticals HAS received final approval from the US Food and Drug Administration (USFDA) for its generic Dasatinib tablets.
Dasatinib tablets are used to treat Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia in adults and children.
Dasatinib is indicated for patients resistant or intolerant to prior therapy, including Imatinib, in chronic, accelerated, or blast phases of leukemia.